Deep Tech Opportunities Report
Computational Bio & Chem
DCVC Bio perspectives on computational/AI approaches to biology and chemistry.
Inside: portfolio updates and analysis on how new medicines are designed, manufactured, and delivered.
Showing 1–32 of 32
Deep Tech Opportunities Report
Deep Tech Opportunity: It’s time to develop better drugs to treat anxiety
Deep Tech Opportunities Report
Deep Tech Opportunity: It’s time to overhaul regulation and reimbursement for one-and-done treatments
Deep Tech Opportunities Report
Deep Tech Opportunity: Third-generation gene therapy companies are advancing toward cures for major diseases that can be treated in no other way
Company Profile
Built to break barriers: How Grove Biopharma is architecting its way around traditional drug limits
News
Latus Bio finds a better way to deliver genes to cells deep in the brain to help patients with neurodegeneration
News
Creyon Bio deal with Lilly brings up to $1 billion in payments for research on RNA-targeting drugs
News
Manufacturing cancer-killing T cells inside the body
DCVC Announcements
DCVC closes $700 million+ in new funds for a healthier planet and healthier lives; releases second-annual Deep Tech Opportunities Report and first-annual DCVC Climate Impact Report
News
DCVC Bio III closes at $400 million
News
Umoja gets FDA approval to begin clinical trials of its transformative in vivo gene therapy for cancer
News
DCVC co-leads $12.5 million financing for Kanvas Biosciences to boost immunotherapy by mapping beneficial gut bacteria
Snapshot
How Noetik uses images to give its AI model a deeper understanding of cancer
Q&A
Ascend partners with industry to drive down gene therapy cost for better patient access
News
Radionetics announces $52.5 million Series A round co-led by DCVC Bio
Deep Tech Opportunities Report
Cryptography for the real world
Deep Tech Opportunities Report
The Engineered Patient
News
MycoWorks expands to address the soaring need for high-end leather alternatives
News
With Assets from Federation Bio, Kanvas Aims to Replace Imprecise Microbiome Therapies with a Single, Rationally Designed Pill
News
DCVC Leads $14 Million Seed Round for Noetik
Deep Tech Opportunities Report
Predictive drug development: toward efficacy from the get-go
News
DCVC leads $12M financing for Kanvas Biosciences to map the human body’s undiscovered territory: the microbiome
News
DCVC leads $13 million seed funding for ShennonBio—revolutionizing immunotherapy through immune cell profiling at unprecedented accuracy, speed
DCVC Announcements
DCVC Welcomes 2022
News
Biology-as-a-Platform in the Fight Against Cancer: Freenome Raises $270m Series C
Thoughts
Using Biology-as-a-Platform to Move from Treatment to Cure
News
Life sciences and Deep Tech: The next set of solutions to the next set of problems
Thoughts
An Update on How Deep Tech is Arming the Fight Against COVID-19
Thoughts
Powering a Comprehensive Response to the COVID-19 Crisis Through Deep Tech
News
Reimagining biologics: AbCellera and Novartis partner to find new disease treatments
News
AbCellera Raises $10M Series A: Deep Search for the Immune System
News